MX2022014387A - Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). - Google Patents
Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva).Info
- Publication number
- MX2022014387A MX2022014387A MX2022014387A MX2022014387A MX2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A
- Authority
- MX
- Mexico
- Prior art keywords
- modified vaccinia
- smva
- vaccinia ankara
- mva
- vaccines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026127P | 2020-05-17 | 2020-05-17 | |
| US202063044033P | 2020-06-25 | 2020-06-25 | |
| US202063113810P | 2020-11-13 | 2020-11-13 | |
| US202163161371P | 2021-03-15 | 2021-03-15 | |
| PCT/US2021/032821 WO2021236550A1 (en) | 2020-05-17 | 2021-05-17 | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014387A true MX2022014387A (es) | 2023-04-11 |
Family
ID=78708032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014387A MX2022014387A (es) | 2020-05-17 | 2021-05-17 | Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230323389A1 (https=) |
| EP (1) | EP4153228A4 (https=) |
| JP (2) | JP7788403B2 (https=) |
| KR (1) | KR20230012583A (https=) |
| CN (1) | CN116348132A (https=) |
| AU (1) | AU2021276265A1 (https=) |
| BR (1) | BR112022023173A2 (https=) |
| CA (1) | CA3183016A1 (https=) |
| IL (1) | IL298210A (https=) |
| MX (1) | MX2022014387A (https=) |
| WO (1) | WO2021236550A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| WO2023056284A1 (en) * | 2021-09-29 | 2023-04-06 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronavirus infection |
| WO2023092021A1 (en) * | 2021-11-17 | 2023-05-25 | City Of Hope | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
| EP4558171A1 (en) * | 2022-07-22 | 2025-05-28 | City of Hope | Synthetic modified vaccinia ankara vaccines to stimulate orthopox and monkeypox virus immunity |
| EP4316514A1 (en) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
| TW202426045A (zh) * | 2022-10-07 | 2024-07-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物 |
| WO2026030724A1 (en) * | 2024-08-01 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040014034A1 (en) | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| EP2363493B1 (en) | 2003-02-20 | 2012-11-14 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel insertion sites in pox vectors |
| US20070092936A1 (en) * | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
| WO2005028634A2 (en) * | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2006071250A2 (en) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| DK2062023T4 (en) | 2006-08-25 | 2017-02-20 | The Government Of The Us Secretary Dept Of Health And Human Services | INTERGENIC SITES BETWEEN CONSERVATED GENES THROUGH MODIFIED VACCINIA ANKARA (VAT) VACCINIAVIRUS |
| DK2488649T3 (da) | 2009-10-16 | 2019-06-17 | Us Health | Rekombinant modificeret vaccinia ankara (mva)-vaccinia-virus indeholdende restrukturerede insertionssteder |
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| WO2017209053A1 (ja) | 2016-05-30 | 2017-12-07 | アステラス製薬株式会社 | 新規な遺伝子組換えワクシニアウイルス |
| JP2019535311A (ja) | 2016-11-02 | 2019-12-12 | デイビッド エバンス， | 合成キメラポックスウイルス |
| WO2018234506A2 (en) | 2017-06-21 | 2018-12-27 | Transgene Sa | PERSONALIZED VACCINE |
| WO2019014569A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
| EP3788142A4 (en) * | 2018-05-02 | 2022-04-27 | Tonix Pharma Holdings Limited | SYNTHETIC CHIMERIC VACCINE VIRUS |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン |
| CA3168836A1 (en) | 2020-02-03 | 2021-08-12 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| KR20220144416A (ko) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| IL295548A (en) * | 2020-02-14 | 2022-10-01 | Altimmune Inc | Immunogenic compositions of the corona virus and their uses |
| EP4103231A4 (en) | 2020-02-14 | 2024-03-27 | Geovax, Inc. | VACCINES AND THEIR USES TO INDUCE AN IMMUNE RESPONSE AGAINST SARS-COV2 |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| KR20220165731A (ko) * | 2020-02-26 | 2022-12-15 | 토닉스 파마 리미티드 | Sars-cov-2 바이러스에 대한 재조합 폭스바이러스 기반 백신 |
| WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
| US11202753B1 (en) * | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| JP2023517286A (ja) | 2020-03-13 | 2023-04-25 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 免疫応答を誘導するための組成物及び方法 |
| US20210299245A1 (en) | 2020-03-31 | 2021-09-30 | Sementis Limited | Attenuated poxvirus vector based vaccine for protection against covid-19 |
| US20230143228A1 (en) | 2020-04-21 | 2023-05-11 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
-
2021
- 2021-05-17 EP EP21809653.5A patent/EP4153228A4/en active Pending
- 2021-05-17 US US17/999,170 patent/US20230323389A1/en active Pending
- 2021-05-17 BR BR112022023173A patent/BR112022023173A2/pt unknown
- 2021-05-17 KR KR1020227044240A patent/KR20230012583A/ko active Pending
- 2021-05-17 WO PCT/US2021/032821 patent/WO2021236550A1/en not_active Ceased
- 2021-05-17 JP JP2022570108A patent/JP7788403B2/ja active Active
- 2021-05-17 MX MX2022014387A patent/MX2022014387A/es unknown
- 2021-05-17 CA CA3183016A patent/CA3183016A1/en active Pending
- 2021-05-17 AU AU2021276265A patent/AU2021276265A1/en active Pending
- 2021-05-17 IL IL298210A patent/IL298210A/en unknown
- 2021-05-17 CN CN202180059838.6A patent/CN116348132A/zh active Pending
-
2025
- 2025-04-18 US US19/183,257 patent/US12584146B2/en active Active
- 2025-12-08 JP JP2025238238A patent/JP2026041921A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022023173A2 (pt) | 2022-12-27 |
| US20250313858A1 (en) | 2025-10-09 |
| KR20230012583A (ko) | 2023-01-26 |
| EP4153228A1 (en) | 2023-03-29 |
| CA3183016A1 (en) | 2021-11-25 |
| US20230323389A1 (en) | 2023-10-12 |
| AU2021276265A1 (en) | 2022-12-08 |
| WO2021236550A1 (en) | 2021-11-25 |
| EP4153228A4 (en) | 2024-07-10 |
| CN116348132A (zh) | 2023-06-27 |
| JP2026041921A (ja) | 2026-03-10 |
| JP2023526073A (ja) | 2023-06-20 |
| US12584146B2 (en) | 2026-03-24 |
| JP7788403B2 (ja) | 2025-12-18 |
| IL298210A (en) | 2023-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022014387A (es) | Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). | |
| MX2019003116A (es) | Nueva vacuna contra la gripe porcina. | |
| CO2022010342A2 (es) | Composiciones y métodos para modular simultáneamente la expresión de genes | |
| ECSP077264A (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan | |
| CO2021005066A2 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| CY1116108T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| CO2021011892A2 (es) | Arn terapéutico para el cáncer de próstata | |
| PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
| BR0316346A (pt) | Vacina para vìrus do nilo ocidental | |
| MX2021013698A (es) | Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb). | |
| EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
| MX2020009262A (es) | Vectores de parapoxvirus. | |
| CO2021005069A2 (es) | Vacuna de ibv h52 con proteína espicular heteróloga | |
| BR112022014738A2 (pt) | Vetores à base de poxvírus produzidos por dna natural ou sintético e usos dos mesmos | |
| CL2021003063A1 (es) | Arn terapéutico para cáncer de ovario | |
| BRPI0508064A (pt) | flavivìrus, composição de vacina e molécula de ácido nucléico | |
| CL2023003126A1 (es) | Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa | |
| UY39464A (es) | Composiciones y métodos para la prevención y/o tratamiento de la covid-19 | |
| MX2019003317A (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| DE602004032187D1 (de) | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara | |
| AR133423A1 (es) | Vacuna ibv con proteína de espícula dmv/1639 heteróloga | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. | |
| CY1121805T1 (el) | Νουκλεϊνικο οξυ που περιλαμβανει ή κωδικοποιει στελεχος-βροχο ιστονης και πολυ(α) αλληλουχια ή σημα πολυαδενυλιωσης για αυξηση της εκφρασης ενος κωδικοποιημενου αντιγονου ογκου |